2023
Potential of Dietary HDAC2i in Breast Cancer Patients Receiving PD-1/PD-L1 Inhibitors
Wang Y, Lu L, Ling C, Zhang P, Han R. Potential of Dietary HDAC2i in Breast Cancer Patients Receiving PD-1/PD-L1 Inhibitors. Nutrients 2023, 15: 3984. PMID: 37764768, PMCID: PMC10537481, DOI: 10.3390/nu15183984.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsPD-1/PD-L1 inhibitorsPD-L1 inhibitorsICI therapyDietary interventionBC patientsBreast cancerTherapeutic strategiesNovel immune checkpoint inhibitorsHDAC2 inhibitorsIntegrated therapeutic strategiesOptimal clinical benefitKaplan-Meier plotter platformNew therapeutic strategiesAnti-cancer effectsCheckpoint inhibitorsSupportive therapyClinical benefitHigh morbidityCombination therapyTreatment outcomesLethal malignancyTherapeutic effectEffective treatmentPrognostic analysis
2020
Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors
Yao L, Jia G, Lu L, Bao Y, Ma W. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. International Immunopharmacology 2020, 85: 106628. PMID: 32474388, DOI: 10.1016/j.intimp.2020.106628.Peer-Reviewed Original ResearchConceptsImmune-related adverse effectsImmune checkpoint inhibitorsICI therapyCheckpoint inhibitorsCancer patientsPredictive biomarkersTumor respondersAnti-PD-1/PD-L1 immunotherapyCell death protein 1 (PD-1) pathwayT-lymphocyte-associated antigen 4PD-L1 immunotherapyVariety of malignanciesAdvanced human cancersConventional anticancer therapiesDegree of severityProtein 1 pathwayNew potential mechanismAntigen-4Cancer immunotherapyToxicity profileImmunotherapyTherapyPatientsAdverse effectsAnticancer therapy